世界の経口投与ワクチン市場インサイト・予測（～2027年）

• 英文タイトル：Global Vaccines Administered Orally Market Insights and Forecast to 2027

• レポートコード：QY2108PAL4049
• 出版社/出版日：QYResearch / 2021年8月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、126ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

本調査資料は経口投与ワクチンの世界市場の現状について調査・分析し、2027年までの市場を予測しました。経口投与ワクチンの世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（ヒト用、動物用）、用途別市場規模（公共用、個人用）、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。

・経口投与ワクチンの世界市場概要
・メーカー別の競争状況、市場シェア
・経口投与ワクチンの種類別市場規模：ヒト用、動物用
・経口投与ワクチンの用途別市場規模：公共用、個人用
・北米の経口投与ワクチン市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ）
・ヨーロッパの経口投与ワクチン市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス）
・アジアの経口投与ワクチン市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国）
・中南米の経口投与ワクチン市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル）
・中東・アフリカの経口投与ワクチン市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア）
・企業情報：Merck、GSK、Sanofi、Lanzhou Institute、Serum Institute、Valneva、Shanghai United Cell、Bibcol、PaxVax、Vabiotech、Tiantan Biological、EuBiologics、Panacea Biotec Ltd、Bio-Med、Halfkin Bio-Pharmaceuticals
・経口投与ワクチンのバリューチェーン・販売チャネル分析
・経口投与ワクチンの世界市場動向

Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.

Market Analysis and Insights: Global Vaccines Administered Orally Market
The global Vaccines Administered Orally market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.

Global Vaccines Administered Orally Scope and Segment
Vaccines Administered Orally market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Vaccines Administered Orally market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Human
Animal

Segment by Application
Public
Private

By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

1 Study Coverage
1.1 Vaccines Administered Orally Product Introduction
1.2 Market by Type
1.2.1 Global Vaccines Administered Orally Market Size Growth Rate by Type
1.2.2 Human
1.2.3 Animal
1.3 Market by Application
1.3.1 Global Vaccines Administered Orally Market Size Growth Rate by Application
1.3.2 Public
1.3.3 Private
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Vaccines Administered Orally Sales Estimates and Forecasts 2016-2027
2.2 Global Vaccines Administered Orally Revenue Estimates and Forecasts 2016-2027
2.3 Global Vaccines Administered Orally Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Vaccines Administered Orally Regions by Sales
2.4.1 Global Top Vaccines Administered Orally Regions by Sales (2016-2021)
2.4.2 Global Top Vaccines Administered Orally Regions by Sales (2022-2027)
2.5 Global Top Vaccines Administered Orally Regions by Revenue
2.5.1 Global Top Vaccines Administered Orally Regions by Revenue (2016-2021)
2.5.2 Global Top Vaccines Administered Orally Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Vaccines Administered Orally Sales by Manufacturers
3.1.1 Global Top Vaccines Administered Orally Manufacturers by Sales (2016-2021)
3.1.2 Global Top Vaccines Administered Orally Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Vaccines Administered Orally Sales in 2020
3.2 Global Vaccines Administered Orally Revenue by Manufacturers
3.2.1 Global Top Vaccines Administered Orally Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Vaccines Administered Orally Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Vaccines Administered Orally Revenue in 2020
3.3 Global Vaccines Administered Orally Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Vaccines Administered Orally Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Vaccines Administered Orally Sales by Type
4.1.1 Global Vaccines Administered Orally Historical Sales by Type (2016-2021)
4.1.2 Global Vaccines Administered Orally Forecasted Sales by Type (2022-2027)
4.1.3 Global Vaccines Administered Orally Sales Market Share by Type (2016-2027)
4.2 Global Vaccines Administered Orally Revenue by Type
4.2.1 Global Vaccines Administered Orally Historical Revenue by Type (2016-2021)
4.2.2 Global Vaccines Administered Orally Forecasted Revenue by Type (2022-2027)
4.2.3 Global Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
4.3 Global Vaccines Administered Orally Price by Type
4.3.1 Global Vaccines Administered Orally Price by Type (2016-2021)
4.3.2 Global Vaccines Administered Orally Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Vaccines Administered Orally Sales by Application
5.1.1 Global Vaccines Administered Orally Historical Sales by Application (2016-2021)
5.1.2 Global Vaccines Administered Orally Forecasted Sales by Application (2022-2027)
5.1.3 Global Vaccines Administered Orally Sales Market Share by Application (2016-2027)
5.2 Global Vaccines Administered Orally Revenue by Application
5.2.1 Global Vaccines Administered Orally Historical Revenue by Application (2016-2021)
5.2.2 Global Vaccines Administered Orally Forecasted Revenue by Application (2022-2027)
5.2.3 Global Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
5.3 Global Vaccines Administered Orally Price by Application
5.3.1 Global Vaccines Administered Orally Price by Application (2016-2021)
5.3.2 Global Vaccines Administered Orally Price Forecast by Application (2022-2027)

6 North America
6.1 North America Vaccines Administered Orally Market Size by Type
6.1.1 North America Vaccines Administered Orally Sales by Type (2016-2027)
6.1.2 North America Vaccines Administered Orally Revenue by Type (2016-2027)
6.2 North America Vaccines Administered Orally Market Size by Application
6.2.1 North America Vaccines Administered Orally Sales by Application (2016-2027)
6.2.2 North America Vaccines Administered Orally Revenue by Application (2016-2027)
6.3 North America Vaccines Administered Orally Market Size by Country
6.3.1 North America Vaccines Administered Orally Sales by Country (2016-2027)
6.3.2 North America Vaccines Administered Orally Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Vaccines Administered Orally Market Size by Type
7.1.1 Europe Vaccines Administered Orally Sales by Type (2016-2027)
7.1.2 Europe Vaccines Administered Orally Revenue by Type (2016-2027)
7.2 Europe Vaccines Administered Orally Market Size by Application
7.2.1 Europe Vaccines Administered Orally Sales by Application (2016-2027)
7.2.2 Europe Vaccines Administered Orally Revenue by Application (2016-2027)
7.3 Europe Vaccines Administered Orally Market Size by Country
7.3.1 Europe Vaccines Administered Orally Sales by Country (2016-2027)
7.3.2 Europe Vaccines Administered Orally Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Vaccines Administered Orally Market Size by Type
8.1.1 Asia Pacific Vaccines Administered Orally Sales by Type (2016-2027)
8.1.2 Asia Pacific Vaccines Administered Orally Revenue by Type (2016-2027)
8.2 Asia Pacific Vaccines Administered Orally Market Size by Application
8.2.1 Asia Pacific Vaccines Administered Orally Sales by Application (2016-2027)
8.2.2 Asia Pacific Vaccines Administered Orally Revenue by Application (2016-2027)
8.3 Asia Pacific Vaccines Administered Orally Market Size by Region
8.3.1 Asia Pacific Vaccines Administered Orally Sales by Region (2016-2027)
8.3.2 Asia Pacific Vaccines Administered Orally Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Vaccines Administered Orally Market Size by Type
9.1.1 Latin America Vaccines Administered Orally Sales by Type (2016-2027)
9.1.2 Latin America Vaccines Administered Orally Revenue by Type (2016-2027)
9.2 Latin America Vaccines Administered Orally Market Size by Application
9.2.1 Latin America Vaccines Administered Orally Sales by Application (2016-2027)
9.2.2 Latin America Vaccines Administered Orally Revenue by Application (2016-2027)
9.3 Latin America Vaccines Administered Orally Market Size by Country
9.3.1 Latin America Vaccines Administered Orally Sales by Country (2016-2027)
9.3.2 Latin America Vaccines Administered Orally Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia

10 Middle East and Africa
10.1 Middle East and Africa Vaccines Administered Orally Market Size by Type
10.1.1 Middle East and Africa Vaccines Administered Orally Sales by Type (2016-2027)
10.1.2 Middle East and Africa Vaccines Administered Orally Revenue by Type (2016-2027)
10.2 Middle East and Africa Vaccines Administered Orally Market Size by Application
10.2.1 Middle East and Africa Vaccines Administered Orally Sales by Application (2016-2027)
10.2.2 Middle East and Africa Vaccines Administered Orally Revenue by Application (2016-2027)
10.3 Middle East and Africa Vaccines Administered Orally Market Size by Country
10.3.1 Middle East and Africa Vaccines Administered Orally Sales by Country (2016-2027)
10.3.2 Middle East and Africa Vaccines Administered Orally Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Merck Vaccines Administered Orally Product Description
11.1.5 Merck Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 GSK Vaccines Administered Orally Product Description
11.2.5 GSK Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Sanofi Vaccines Administered Orally Product Description
11.3.5 Sanofi Recent Developments
11.4 Lanzhou Institute
11.4.1 Lanzhou Institute Corporation Information
11.4.2 Lanzhou Institute Overview
11.4.3 Lanzhou Institute Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Lanzhou Institute Vaccines Administered Orally Product Description
11.4.5 Lanzhou Institute Recent Developments
11.5 Serum Institute
11.5.1 Serum Institute Corporation Information
11.5.2 Serum Institute Overview
11.5.3 Serum Institute Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Serum Institute Vaccines Administered Orally Product Description
11.5.5 Serum Institute Recent Developments
11.6 Valneva
11.6.1 Valneva Corporation Information
11.6.2 Valneva Overview
11.6.3 Valneva Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Valneva Vaccines Administered Orally Product Description
11.6.5 Valneva Recent Developments
11.7 Shanghai United Cell
11.7.1 Shanghai United Cell Corporation Information
11.7.2 Shanghai United Cell Overview
11.7.3 Shanghai United Cell Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Shanghai United Cell Vaccines Administered Orally Product Description
11.7.5 Shanghai United Cell Recent Developments
11.8 Bibcol
11.8.1 Bibcol Corporation Information
11.8.2 Bibcol Overview
11.8.3 Bibcol Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Bibcol Vaccines Administered Orally Product Description
11.8.5 Bibcol Recent Developments
11.9 PaxVax
11.9.1 PaxVax Corporation Information
11.9.2 PaxVax Overview
11.9.3 PaxVax Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 PaxVax Vaccines Administered Orally Product Description
11.9.5 PaxVax Recent Developments
11.10 Vabiotech
11.10.1 Vabiotech Corporation Information
11.10.2 Vabiotech Overview
11.10.3 Vabiotech Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 Vabiotech Vaccines Administered Orally Product Description
11.10.5 Vabiotech Recent Developments
11.11 Tiantan Biological
11.11.1 Tiantan Biological Corporation Information
11.11.2 Tiantan Biological Overview
11.11.3 Tiantan Biological Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Tiantan Biological Vaccines Administered Orally Product Description
11.11.5 Tiantan Biological Recent Developments
11.12 EuBiologics
11.12.1 EuBiologics Corporation Information
11.12.2 EuBiologics Overview
11.12.3 EuBiologics Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 EuBiologics Vaccines Administered Orally Product Description
11.12.5 EuBiologics Recent Developments
11.13 Panacea Biotec Ltd
11.13.1 Panacea Biotec Ltd Corporation Information
11.13.2 Panacea Biotec Ltd Overview
11.13.3 Panacea Biotec Ltd Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.13.4 Panacea Biotec Ltd Vaccines Administered Orally Product Description
11.13.5 Panacea Biotec Ltd Recent Developments
11.14 Bio-Med
11.14.1 Bio-Med Corporation Information
11.14.2 Bio-Med Overview
11.14.3 Bio-Med Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.14.4 Bio-Med Vaccines Administered Orally Product Description
11.14.5 Bio-Med Recent Developments
11.15 Halfkin Bio-Pharmaceuticals
11.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
11.15.2 Halfkin Bio-Pharmaceuticals Overview
11.15.3 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Sales, Price, Revenue and Gross Margin (2016-2021)
11.15.4 Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Product Description
11.15.5 Halfkin Bio-Pharmaceuticals Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Vaccines Administered Orally Value Chain Analysis
12.2 Vaccines Administered Orally Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaccines Administered Orally Production Mode & Process
12.4 Vaccines Administered Orally Sales and Marketing
12.4.1 Vaccines Administered Orally Sales Channels
12.4.2 Vaccines Administered Orally Distributors
12.5 Vaccines Administered Orally Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Vaccines Administered Orally Industry Trends
13.2 Vaccines Administered Orally Market Drivers
13.3 Vaccines Administered Orally Market Challenges
13.4 Vaccines Administered Orally Market Restraints

14 Key Findings in The Global Vaccines Administered Orally Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Vaccines Administered Orally Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Human
Table 3. Major Manufacturers of Animal
Table 4. Global Vaccines Administered Orally Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 5. Global Vaccines Administered Orally Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Vaccines Administered Orally Sales by Region (2016-2021) & (K Units)
Table 7. Global Vaccines Administered Orally Sales Market Share by Region (2016-2021)
Table 8. Global Vaccines Administered Orally Sales by Region (2022-2027) & (K Units)
Table 9. Global Vaccines Administered Orally Sales Market Share by Region (2022-2027)
Table 10. Global Vaccines Administered Orally Revenue by Region (2016-2021) & (US$ Million)
Table 11. Global Vaccines Administered Orally Revenue Market Share by Region (2016-2021)
Table 12. Global Vaccines Administered Orally Revenue by Region (2022-2027) & (US$ Million)
Table 13. Global Vaccines Administered Orally Revenue Market Share by Region (2022-2027)
Table 14. Global Vaccines Administered Orally Sales by Manufacturers (2016-2021) & (K Units)
Table 15. Global Vaccines Administered Orally Sales Share by Manufacturers (2016-2021)
Table 16. Global Vaccines Administered Orally Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 17. Global Vaccines Administered Orally Revenue Share by Manufacturers (2016-2021)
Table 18. Vaccines Administered Orally Price by Manufacturers 2016-2021 (US$/Unit)
Table 19. Global Vaccines Administered Orally Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Vaccines Administered Orally by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccines Administered Orally as of 2020)
Table 21. Vaccines Administered Orally Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Vaccines Administered Orally Product Offered
Table 23. Date of Manufacturers Enter into Vaccines Administered Orally Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 26. Global Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 27. Global Vaccines Administered Orally Sales Share by Type (2016-2021)
Table 28. Global Vaccines Administered Orally Sales Share by Type (2022-2027)
Table 29. Global Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 30. Global Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 31. Global Vaccines Administered Orally Revenue Share by Type (2016-2021)
Table 32. Global Vaccines Administered Orally Revenue Share by Type (2022-2027)
Table 33. Vaccines Administered Orally Price by Type (2016-2021) & (US$/Unit)
Table 34. Global Vaccines Administered Orally Price Forecast by Type (2022-2027) & (US$/Unit)
Table 35. Global Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 36. Global Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 37. Global Vaccines Administered Orally Sales Share by Application (2016-2021)
Table 38. Global Vaccines Administered Orally Sales Share by Application (2022-2027)
Table 39. Global Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 40. Global Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 41. Global Vaccines Administered Orally Revenue Share by Application (2016-2021)
Table 42. Global Vaccines Administered Orally Revenue Share by Application (2022-2027)
Table 43. Vaccines Administered Orally Price by Application (2016-2021) & (US$/Unit)
Table 44. Global Vaccines Administered Orally Price Forecast by Application (2022-2027) & (US$/Unit)
Table 45. North America Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 46. North America Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 47. North America Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 48. North America Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 49. North America Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 50. North America Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 51. North America Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 52. North America Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 53. North America Vaccines Administered Orally Sales by Country (2016-2021) & (K Units)
Table 54. North America Vaccines Administered Orally Sales by Country (2022-2027) & (K Units)
Table 55. North America Vaccines Administered Orally Revenue by Country (2016-2021) & (US$ Million)
Table 56. North America Vaccines Administered Orally Revenue by Country (2022-2027) & (US$ Million)
Table 57. Europe Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 58. Europe Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 59. Europe Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 60. Europe Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 61. Europe Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 62. Europe Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 63. Europe Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 64. Europe Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 65. Europe Vaccines Administered Orally Sales by Country (2016-2021) & (K Units)
Table 66. Europe Vaccines Administered Orally Sales by Country (2022-2027) & (K Units)
Table 67. Europe Vaccines Administered Orally Revenue by Country (2016-2021) & (US$ Million)
Table 68. Europe Vaccines Administered Orally Revenue by Country (2022-2027) & (US$ Million)
Table 69. Asia Pacific Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 70. Asia Pacific Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 71. Asia Pacific Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 72. Asia Pacific Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 73. Asia Pacific Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 74. Asia Pacific Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 75. Asia Pacific Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 76. Asia Pacific Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 77. Asia Pacific Vaccines Administered Orally Sales by Region (2016-2021) & (K Units)
Table 78. Asia Pacific Vaccines Administered Orally Sales by Region (2022-2027) & (K Units)
Table 79. Asia Pacific Vaccines Administered Orally Revenue by Region (2016-2021) & (US$ Million)
Table 80. Asia Pacific Vaccines Administered Orally Revenue by Region (2022-2027) & (US$ Million)
Table 81. Latin America Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 82. Latin America Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 83. Latin America Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 84. Latin America Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 85. Latin America Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 86. Latin America Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 87. Latin America Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 88. Latin America Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 89. Latin America Vaccines Administered Orally Sales by Country (2016-2021) & (K Units)
Table 90. Latin America Vaccines Administered Orally Sales by Country (2022-2027) & (K Units)
Table 91. Latin America Vaccines Administered Orally Revenue by Country (2016-2021) & (US$ Million)
Table 92. Latin America Vaccines Administered Orally Revenue by Country (2022-2027) & (US$ Million)
Table 93. Middle East and Africa Vaccines Administered Orally Sales by Type (2016-2021) & (K Units)
Table 94. Middle East and Africa Vaccines Administered Orally Sales by Type (2022-2027) & (K Units)
Table 95. Middle East and Africa Vaccines Administered Orally Revenue by Type (2016-2021) & (US$ Million)
Table 96. Middle East and Africa Vaccines Administered Orally Revenue by Type (2022-2027) & (US$ Million)
Table 97. Middle East and Africa Vaccines Administered Orally Sales by Application (2016-2021) & (K Units)
Table 98. Middle East and Africa Vaccines Administered Orally Sales by Application (2022-2027) & (K Units)
Table 99. Middle East and Africa Vaccines Administered Orally Revenue by Application (2016-2021) & (US$ Million)
Table 100. Middle East and Africa Vaccines Administered Orally Revenue by Application (2022-2027) & (US$ Million)
Table 101. Middle East and Africa Vaccines Administered Orally Sales by Country (2016-2021) & (K Units)
Table 102. Middle East and Africa Vaccines Administered Orally Sales by Country (2022-2027) & (K Units)
Table 103. Middle East and Africa Vaccines Administered Orally Revenue by Country (2016-2021) & (US$ Million)
Table 104. Middle East and Africa Vaccines Administered Orally Revenue by Country (2022-2027) & (US$ Million)
Table 105. Merck Corporation Information
Table 106. Merck Description and Major Businesses
Table 107. Merck Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 108. Merck Vaccines Administered Orally Product
Table 109. Merck Recent Developments
Table 110. GSK Corporation Information
Table 111. GSK Description and Major Businesses
Table 112. GSK Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. GSK Vaccines Administered Orally Product
Table 114. GSK Recent Developments
Table 115. Sanofi Corporation Information
Table 116. Sanofi Description and Major Businesses
Table 117. Sanofi Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. Sanofi Vaccines Administered Orally Product
Table 119. Sanofi Recent Developments
Table 120. Lanzhou Institute Corporation Information
Table 121. Lanzhou Institute Description and Major Businesses
Table 122. Lanzhou Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Lanzhou Institute Vaccines Administered Orally Product
Table 124. Lanzhou Institute Recent Developments
Table 125. Serum Institute Corporation Information
Table 126. Serum Institute Description and Major Businesses
Table 127. Serum Institute Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. Serum Institute Vaccines Administered Orally Product
Table 129. Serum Institute Recent Developments
Table 130. Valneva Corporation Information
Table 131. Valneva Description and Major Businesses
Table 132. Valneva Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Valneva Vaccines Administered Orally Product
Table 134. Valneva Recent Developments
Table 135. Shanghai United Cell Corporation Information
Table 136. Shanghai United Cell Description and Major Businesses
Table 137. Shanghai United Cell Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Shanghai United Cell Vaccines Administered Orally Product
Table 139. Shanghai United Cell Recent Developments
Table 140. Bibcol Corporation Information
Table 141. Bibcol Description and Major Businesses
Table 142. Bibcol Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. Bibcol Vaccines Administered Orally Product
Table 144. Bibcol Recent Developments
Table 145. PaxVax Corporation Information
Table 146. PaxVax Description and Major Businesses
Table 147. PaxVax Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 148. PaxVax Vaccines Administered Orally Product
Table 149. PaxVax Recent Developments
Table 150. Vabiotech Corporation Information
Table 151. Vabiotech Description and Major Businesses
Table 152. Vabiotech Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 153. Vabiotech Vaccines Administered Orally Product
Table 154. Vabiotech Recent Developments
Table 155. Tiantan Biological Corporation Information
Table 156. Tiantan Biological Description and Major Businesses
Table 157. Tiantan Biological Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Tiantan Biological Vaccines Administered Orally Product
Table 159. Tiantan Biological Recent Developments
Table 160. EuBiologics Corporation Information
Table 161. EuBiologics Description and Major Businesses
Table 162. EuBiologics Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 163. EuBiologics Vaccines Administered Orally Product
Table 164. EuBiologics Recent Developments
Table 165. Panacea Biotec Ltd Corporation Information
Table 166. Panacea Biotec Ltd Description and Major Businesses
Table 167. Panacea Biotec Ltd Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 168. Panacea Biotec Ltd Vaccines Administered Orally Product
Table 169. Panacea Biotec Ltd Recent Developments
Table 170. Bio-Med Corporation Information
Table 171. Bio-Med Description and Major Businesses
Table 172. Bio-Med Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 173. Bio-Med Vaccines Administered Orally Product
Table 174. Bio-Med Recent Developments
Table 175. Halfkin Bio-Pharmaceuticals Corporation Information
Table 176. Halfkin Bio-Pharmaceuticals Description and Major Businesses
Table 177. Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 178. Halfkin Bio-Pharmaceuticals Vaccines Administered Orally Product
Table 179. Halfkin Bio-Pharmaceuticals Recent Developments
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Vaccines Administered Orally Distributors List
Table 183. Vaccines Administered Orally Customers List
Table 184. Vaccines Administered Orally Market Trends
Table 185. Vaccines Administered Orally Market Drivers
Table 186. Vaccines Administered Orally Market Challenges
Table 187. Vaccines Administered Orally Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccines Administered Orally Product Picture
Figure 2. Global Vaccines Administered Orally Market Share by Type in 2020 & 2027
Figure 3. Human Product Picture
Figure 4. Animal Product Picture
Figure 5. Global Vaccines Administered Orally Market Share by Application in 2020 & 2027
Figure 6. Public
Figure 7. Private
Figure 8. Vaccines Administered Orally Report Years Considered
Figure 9. Global Vaccines Administered Orally Sales 2016-2027 (K Units)
Figure 10. Global Vaccines Administered Orally Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Vaccines Administered Orally Revenue 2016-2027 (US$ Million)
Figure 12. Global Vaccines Administered Orally Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 13. Global Vaccines Administered Orally Sales Market Share by Region (2016-2021)
Figure 14. Global Vaccines Administered Orally Sales Market Share by Region (2022-2027)
Figure 15. North America Vaccines Administered Orally Sales YoY (2016-2027) & (K Units)
Figure 16. North America Vaccines Administered Orally Revenue YoY (2016-2027) & (US$ Million)
Figure 17. Europe Vaccines Administered Orally Sales YoY (2016-2027) & (K Units)
Figure 18. Europe Vaccines Administered Orally Revenue YoY (2016-2027) & (US$ Million)
Figure 19. Asia-Pacific Vaccines Administered Orally Sales YoY (2016-2027) & (K Units)
Figure 20. Asia-Pacific Vaccines Administered Orally Revenue YoY (2016-2027) & (US$ Million)
Figure 21. Latin America Vaccines Administered Orally Sales YoY (2016-2027) & (K Units)
Figure 22. Latin America Vaccines Administered Orally Revenue YoY (2016-2027) & (US$ Million)
Figure 23. Middle East & Africa Vaccines Administered Orally Sales YoY (2016-2027) & (K Units)
Figure 24. Middle East & Africa Vaccines Administered Orally Revenue YoY (2016-2027) & (US$ Million)
Figure 25. The Top 10 and Top 5 Players Market Share by Vaccines Administered Orally Sales in 2020
Figure 26. The Top 10 and Top 5 Players Market Share by Vaccines Administered Orally Revenue in 2020
Figure 27. Vaccines Administered Orally Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 28. Global Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 29. Global Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 30. Global Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 31. Global Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 32. North America Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 33. North America Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 34. North America Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 35. North America Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 36. North America Vaccines Administered Orally Sales Share by Country (2016-2027)
Figure 37. North America Vaccines Administered Orally Revenue Share by Country (2016-2027)
Figure 38. United States Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 39. Canada Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 40. Europe Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 41. Europe Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 42. Europe Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 43. Europe Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 44. Europe Vaccines Administered Orally Sales Share by Country (2016-2027)
Figure 45. Europe Vaccines Administered Orally Revenue Share by Country (2016-2027)
Figure 46. Germany Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 47. France Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 48. U.K. Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 49. Italy Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 50. Russia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 51. Asia Pacific Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 52. Asia Pacific Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 53. Asia Pacific Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 54. Asia Pacific Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 55. Asia Pacific Vaccines Administered Orally Sales Share by Region (2016-2027)
Figure 56. Asia Pacific Vaccines Administered Orally Revenue Share by Region (2016-2027)
Figure 57. China Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 58. Japan Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 59. South Korea Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 60. India Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 61. Australia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 62. China Taiwan Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 63. Indonesia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 64. Thailand Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 65. Malaysia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 66. Latin America Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 67. Latin America Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 68. Latin America Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 69. Latin America Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 70. Latin America Vaccines Administered Orally Sales Share by Country (2016-2027)
Figure 71. Latin America Vaccines Administered Orally Revenue Share by Country (2016-2027)
Figure 72. Mexico Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 73. Brazil Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 74. Argentina Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 75. Colombia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 76. Middle East and Africa Vaccines Administered Orally Sales Market Share by Type (2016-2027)
Figure 77. Middle East and Africa Vaccines Administered Orally Revenue Market Share by Type (2016-2027)
Figure 78. Middle East and Africa Vaccines Administered Orally Sales Market Share by Application (2016-2027)
Figure 79. Middle East and Africa Vaccines Administered Orally Revenue Market Share by Application (2016-2027)
Figure 80. Middle East and Africa Vaccines Administered Orally Sales Share by Country (2016-2027)
Figure 81. Middle East and Africa Vaccines Administered Orally Revenue Share by Country (2016-2027)
Figure 82. Turkey Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 83. Saudi Arabia Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 84. UAE Vaccines Administered Orally Revenue (2016-2027) & (US$ Million)
Figure 85. Vaccines Administered Orally Value Chain
Figure 86. Vaccines Administered Orally Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

以下、関連資料のご紹介

自己投与薬剤の世界市場 2020年

Global Self-Administered Medication Market 2020 by Company, Regions, Type and Application, Forecast to 2025
GIR201115102 2020年10月 101Pages
本書では、自己投与薬剤の世界市場を調査対象にし、自己投与薬剤の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（経口、皮下、経鼻、経皮、その他）、用途別分析（病院薬局、小売薬局、オンライン薬局）、市場予測（...

口腔内崩壊錠の世界市場 2020年

Global Orally Disintegrating Tablet Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
GIR201106143 2020年10月20日 104Pages
本書では、口腔内崩壊錠の世界市場を調査対象にし、口腔内崩壊錠の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（抗精神病薬、抗てんかん薬、その他）、用途別分析（CNS疾患、消化器疾患、CVS...

B型肝炎ワクチンの世界及び中国市場

Global and China Hepatitis B Vaccines Market Insights, Forecast to 2027
QY2108PAL8845 2021年7月 135Pages
QYResearch社発行の当調査資料ではグローバルにおけるB型肝炎ワクチンの市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、B型肝炎ワクチンの種類別市場規模（酵母由来、CHO由来）、用途別市場規模（子供、大人）も掲載しています。他に、北米...

経口ワクチンの世界及び中国市場

Global and China Oral Vaccines Market Insights, Forecast to 2027
QY2108PAL8903 2021年6月 150Pages
QYResearch社発行の当調査資料ではグローバルにおける経口ワクチンの市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、経口ワクチンの種類別市場規模（ロタウイルスワクチン、コレラワクチン、経口ポリオワクチン）、用途別市場規模（公共用、個人...

渡航者用ワクチンの世界市場 2020年

Global Travelers Vaccines Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
GIR201109873 2020年10月20日 107Pages
本書では、渡航者用ワクチンの世界市場を調査対象にし、渡航者用ワクチンの市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（髄膜炎菌ワクチン、日本脳炎ワクチン、黄熱ワクチン、肝炎ワクチン、コレラ...

鳥インフルエンザワクチンの世界市場 2020年

Global Avian Influenza Vaccines Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
GIR201101313 2020年10月20日 105Pages
本書では、鳥インフルエンザワクチンの世界市場を調査対象にし、鳥インフルエンザワクチンの市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（タイプH5、タイプH9、その他）、用途別分析（鶏肉、鴨...

ワクチンデリバリーの世界市場 2020年

Global Vaccines Delivery Market 2020 by Company, Regions, Type and Application, Forecast to 2025
GIR201115344 2020年10月 108Pages
本書では、ワクチンデリバリーの世界市場を調査対象にし、ワクチンデリバリーの市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（生物学的ベクター、化学担体、その他）、用途別分析（病院、クリニック、研究センター）...

口蹄疫（FMD）ワクチンの世界及び中国市場

Global and China Foot and Mouth Disease (FMD) Vaccines Market Insights, Forecast to 2027
QY2108PAL8829 2021年7月 162Pages
QYResearch社発行の当調査資料ではグローバルにおける口蹄疫（FMD）ワクチンの市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、口蹄疫（FMD）ワクチンの種類別市場規模（緊急ワクチン、従来型ワクチン）、用途別市場規模（牛、豚、羊、山羊...

新興がん用ワクチンの世界市場 2020年

Global Emerging Cancer Vaccines Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
GIR201104094 2020年10月20日 101Pages
本書では、新興がん用ワクチンの世界市場を調査対象にし、新興がん用ワクチンの市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（非遺伝性ワクチン、遺伝性ワクチン）、用途別分析（がん研究センター、...

牛ワクチンの世界市場 2020年

Global Cattle Vaccines Market 2020 by Company, Regions, Type and Application, Forecast to 2025
GIR201113817 2020年10月 106Pages
本書では、牛ワクチンの世界市場を調査対象にし、牛ワクチンの市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（トキソイド、組換え、不活化）、用途別分析（政府入札、市場販売）、市場予測（2021年～2025年）...

自己投与薬剤の世界市場 2020年 Market Overview The global Self-Administered Medication market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Self-Administere…
コンパニオンアニマル用ワクチンの世界市場 2020年 Market Overview The global Companion Animal Vaccines market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Companion Animal Va…
口腔内崩壊錠の世界市場 2020年 Market Overview The global Orally Disintegrating Tablet market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 9.8% in the forecast period of 2020 to 2025 and will expected to reach USD 20280 million by 2025, from USD 13950 million in 2019. The Orally Di…
鳥インフルエンザワクチンの世界市場 2020年 Market Overview The Avian Influenza Vaccines market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizati…
B型肝炎ワクチンの世界及び中国市場 Hepatitis B vaccine is a vaccine that prevents hepatitis B. In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%. The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Deri…